Search

Displaying results 2571 - 2580 of 8974 in total
  1. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in

  2. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … The non-stimulant norepinephrine/dopamine reuptake inhibitor [DB01156] (commonly used for the treatment of depression and for smoking cessation) has also been shown to be effective in the treatment of

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  3. Drug

    Pentoxyverine

    go.drugbank.com/drugs/DB11186
    ApprovedWithdrawn

    [L43942] Other forms of pentoxyverine citrate continue to be marketed. … Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.

  4. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.

  5. Drug

    Isoprenaline

    go.drugbank.com/drugs/DB01064
    ApprovedInvestigational

    Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion

    Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway Diseases
  6. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    to be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  7. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156].

  8. Drug

    (S)-camphor

    go.drugbank.com/drugs/DB11345
    Approved

    (S)-camphor, or L(-)-Camphor, is a stereoisomer of [DB01744], a bicyclic monoterpene known to potentiate both heat and cold sensations [A33087]. … Camphor is a major active ingredient in over-the-counter balms and liniments supplied as topical analgesics by causing sensitization to heat and coolness to relieve minor muscle and joint pain [A33086]

  9. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    [L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115] … These modified cells differentiate to express functional CD18 protein, restoring leukocyte adhesion and extravasation.

  10. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective. … for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance).

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics